Protocol Name: SPARX: Safety and efficacy of sparsentan for patients post kidney transplantation with IgAN or FSGS
Protocol #: TVTX-RE021-426
Indication: Cardiovascular Event Risk Reduction
GFR: ≥25
Principal Investigator: Bernard Fischbach, MD, CCRP
Location: Dallas Transplant Institute, 3604 Live Oak Street, Suite 100, Dallas, TX 75204